“Either a buyout or a distribution deal for all
Post# of 145836
IMO, I don’t see a BO or distribution deal for any other indication outside of HIV and COVID happening in the near future (if that’s what you were implying). The phase 2 trials for NASH, Alzheimer’s, and Cancer need to at least return good intern analysis data before a decent licensing deal is completed. Considering 2 of the trials haven’t begun yet, and the other (cancer) is enrolling slowly, that could be 1-2 years away with historical enrollment rates (although NP has states Dr. L’s dad has 300-400 patients ready for the Alzheimer’s trial).
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)